CompletedNCT06624878

Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

Medication studyAges 18–80China

The study in practice

Understand this study

Listed age limits: 18 years to 80 years.

Study clarity

Study start dateStarted: October 8, 2024

Recruitment status: Completed
Enrollment listed in the registry: 568
Sponsor: Zhejiang Cancer Hospital
Sponsor type: Hospital / academic medical center
Study type: Drug
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: China
Age range: From 18 Years to 80 Years
Official registry ID: NCT06624878
Official title: Show the full official title
Intraoperative Esketamine for Prevention of Depressive Symptoms After Cytoreductive Surgery in Ovarian Cancer: a Controlled, Randomized Clinical Trial

Completed

Hangzhou

FAQ

Who is behind this study?

The study sponsor is Zhejiang Cancer Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including esketamine and placebo.

Who was this study for?

Listed age limits: 18 years to 80 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.